SCHEMBL5137367

SCHEMBL5137367

CCCCN(Cc1ccc(OC)c(C)c1OC)Cc1c(-c2ccccc2)nc(-c2ccccc2)n1CCC

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
C5AR1 P21730 1/20 0.36
BCHE P06276 3/20 0.35
GAA P10253 2/20 0.35
TP53 P04637 2/20 0.35
HDAC1 Q13547 1/20 0.34
DRD2 P14416 1/20 0.34
DRD3 P35462 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34
ALDH1A1 P00352 4/20 0.34
TSHR P16473 4/20 0.34
LMNA P02545 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
ATP4A P20648 1/20 0.34
ATP4B P51164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5138090 0.95 TP53 (0.40) KDM4ESMN1; SMN2C5AR1BCHEGAA
SCHEMBL5135989 0.94 SMN1; SMN2 (0.39) KDM4ESMN1; SMN2CYP1A2CYP2D6CYP2C9
SCHEMBL5136445 0.92 DRD2 (0.38) KDM4ESMN1; SMN2C5AR1BCHEGAA
SCHEMBL5137973 0.92 TP53 (0.41) SMN1; SMN2C5AR1BCHEGAATP53
SCHEMBL5137642 0.92 POLB (0.37) KDM4ESMN1; SMN2C5AR1GAATP53
SCHEMBL5135326 0.90 C5AR1 (0.36) KDM4ESMN1; SMN2C5AR1BCHEGAA
SCHEMBL5070081 0.89 SMN1; SMN2 (0.36) KDM4ESMN1; SMN2CYP1A2CYP2D6CYP2C9
SCHEMBL5070121 0.89 SMN1; SMN2 (0.41) KDM4ESMN1; SMN2C5AR1BCHEGAA
SCHEMBL5134803 0.88 BCHE (0.43) C5AR1BCHE
SCHEMBL5137330 0.86 BCHE (0.43) C5AR1BCHEMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed